Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Journal Article · · Journal of Medicinal Chemistry
DOI:https://doi.org/10.1021/jm501578n· OSTI ID:1168859
 [1];  [2];  [1];  [1];  [1];  [3];  [1];  [4];  [4];  [3];  [4];  [5];  [1];  [6];  [7];  [4];  [7];  [8];  [1];  [4] more »;  [7];  [2];  [2];  [8];  [1] « less
  1. Genentech Inc., South San Francisco, CA (United States). Dept. of Discovery Chemistry
  2. Genentech Inc., South San Francisco, CA (United States). Dept. of Structural Biology
  3. Genentech Inc., South San Francisco, CA (United States). Dept. of Drug Metabolism and Pharmacokinetics
  4. Argenta, Harlow, Essex (United Kingdom). Charles River Early Discovery Facility
  5. Genentech Inc., South San Francisco, CA (United States). Dept. of Biochemical and Cellular Pharmacology
  6. Genentech Inc., South San Francisco, CA (United States). Dept. of Molecular Oncology
  7. Genentech Inc., South San Francisco, CA (United States). Dept. of Biochemical and Cellular Pharmacology
  8. Genentech Inc., South San Francisco, CA (United States). Dept. of Protein Expression
+ Show Author Affiliations
Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). Due to dose-limiting toxicities associated with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-containing EGFR mutants with selectivity over wtEGFR. Here in this paper, we describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochemical properties.
Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
National Institutes of Health (NIH); USDOE Office of Science (SC), Basic Energy Sciences (BES) (SC-22)
Grant/Contract Number:
AC02-05CH11231; AC02-06CH11357
OSTI ID:
1168859
Journal Information:
Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 23 Vol. 57; ISSN 0022-2623
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (53)

Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters journal November 2013
Lead identification of novel and selective TYK2 inhibitors journal September 2013
Resistance in the land of molecular cancer therapeutics journal August 2002
A Medicinal Chemist’s Guide to Molecular Interactions journal July 2010
Identification of C -2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2 journal May 2013
Structure-Based Design of Orally Bioavailable 1 H -Pyrrolo[3,2- c ]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1) journal December 2013
Drug−Protein Adducts:  An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development journal January 2004
Epidermal growth factor receptor mutations in lung cancer journal March 2007
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer journal October 2010
Flying under the radar: the new wave of BCR–ABL inhibitors journal October 2007
EGFR Mutation and Response of Lung Cancer to Gefitinib [Correspondence] journal May 2005
Targeting Targeted Therapy journal May 2004
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib journal August 2004
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib journal May 2005
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP journal January 2008
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor journal August 2002
EGFR Mutations in Non-Small Cell Lung Carcinomas May Predict Response to Gefitinib journal March 2005
Oncogene addiction: setting the stage for molecularly targeted cancer therapy journal December 2007
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways journal August 2004
Gefitinib Induces Apoptosis in the EGFR L858R Non–Small-Cell Lung Cancer Cell Line H3255 journal October 2004
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib journal October 2006
The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor journal June 2007
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers journal March 2013
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor journal January 2012
In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing journal April 2014
Maximizing the Benefits of Off-Target Kinase Inhibitor Activity journal February 2013
Inhibition of EGFR Signaling: All Mutations Are Not Created Equal journal November 2005
Drug discovery for a new generation of covalent drugs journal May 2012
Metabolic Stability Screen for Drug Discovery Using Cassette Analysis and Column Switching journal January 2007
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia journal August 2002
Covalent Modifiers: An Orthogonal Approach to Drug Design journal March 2009
The influence of drug-like concepts on decision-making in medicinal chemistry journal November 2007
The role of ligand efficiency metrics in drug discovery journal January 2014
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib journal May 2004
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib journal February 2005
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer journal September 2009
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor journal August 2002
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy journal June 2004
Gefitinib Induces Apoptosis in the EGFR L858R Non–Small-Cell Lung Cancer Cell Line H3255 journal October 2004
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation journal January 2010
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib journal October 2006
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors journal November 2006
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials journal August 2009
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers journal March 2013
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor journal January 2012
In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing journal April 2014
Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M journal December 2012
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer journal June 2014
Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naïve Malignant Pleural Mesothelioma journal March 2008
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer journal June 2010
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations journal September 2013
First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. journal May 2013
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). journal May 2014

Cited By (10)

Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions journal September 2016
Acetylation of C/EBPα inhibits its granulopoietic function journal March 2016
Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry journal January 2018
Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer journal July 2018
Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations journal March 2019
Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study journal July 2018
Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M journal July 2018
Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations text January 2020
Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations text January 2019
Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations text January 2020

Similar Records

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Journal Article · Tue Jul 15 00:00:00 EDT 2008 · Proc. Natl. Acad. Sci. USA · OSTI ID:1006519
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
Journal Article · Sun Jul 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23105732
Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells
Journal Article · Sat Sep 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23105640

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
60 APPLIED LIFE SCIENCES